comparemela.com

Latest Breaking News On - Dominique costantini - Page 4 : comparemela.com

OSE Immunotherapeutics Announces New European Patent Granted Covering CLEC-1, Novel Myeloid Immune Checkpoint Target For Cancer Immunotherapy

Press release content from Globe Newswire. The AP news staff was not involved in its creation.

United statesElise chiffoleauNicolas poirierDominique costantiniThomas guillotFlorence portejoieGuillaume van renterghemDarren oplandNantes university hospitalEuropean patent officeNantes university at hospitalBoehringer ingelheimLifesci communicationsVeloxis pharmaceuticals incChief executive officerChief scientific officer

OSE Immunotherapeutics Announces New European Patent Granted Covering CLEC-1, Novel Myeloid Immune C

A new protection covering CLEC-1 antagonists until 2037Patent also granted in Japan and notice of allowance granted in the USNANTES, France (BUSINESS WIRE) Regulatory News:OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) (Paris:OSE) today announced the grant of a new patent from the European Patent Offic.

United statesFrance generalElise chiffoleauNicolas poirierDominique costantiniThomas guillotFlorence portejoieGuillaume van renterghemDarren oplandNantes university hospitalEuropean patent officeNantes university at hospitalBoehringer ingelheimLifesci communicationsVeloxis pharmaceuticals incRegulatory news

OSE Immunotherapeutics Reports 2021 Financial Results: Major Progress on its Clinical Programs and a Solid Cash Position to Support its Activities

Shared positive final Phase 3 results for Tedopi in non-small cell lung cancer (NSCLC) patients in secondary resistance after failure with second-line checkpoint inhibitor treatment. Received

United statesFrance generalAlexandre lebeautGuillaume van renterghem lifesciThomas guillotAlexis peyrolesElise chiffoleauDominique costantiniFlorence portejoieDarren oplandEuropean patent officeNantes university at hospitalBoehringer ingelheimAudit committeeAmerican society of hematologyTrademark office

OSE Immunotherapeutics Receives First Notice of Allowance for a US Patent Covering Anti-PD1 Monoclonal Antibody OSE-279 And its Use in Cancer Treatment

21.03.2022 - Regulatory News: OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) (Paris:OSE) today announces that the United States Patent and Trademark Office (USPTO) has issued a first notice of allowance for a patent application covering OSE-279, an . Seite 1

United statesDominique costantiniAmerican society for cancer researchChief executive officerCancer researchNon small cell lung cancerOse immunotherapeutics

OSE Immunotherapeutics Provides Positive Long Term Memory Responses with CoVepiT, its T Lymphocyte Multi-Target Anti-COVID Vaccine

Positive long term immunological results at 6 months in healthy volunteers with strong T cell memory responses against virus proteins. CoVepiT, based on 13 peptides, elicits durable T-cell

Dominique costantiniGuillaume van renterghem lifesciThomas guillotFlorence portejoieDarren oplandNantes university hospitalLifesci communicationsVeloxis pharmaceuticals incBoehringer ingelheimCapacity buildingNon small cell lung cancerVeloxis pharmaceuticalsUniversal registration documentRenterghem lifesci advisors

vimarsana © 2020. All Rights Reserved.